Primary oral etoposide therapy in gestational trophoblastic disease: An update
- 1 July 1986
Abstract
Sixty patients who developed persistent or metastatic gestational trophoblastic disease (GTD) received primary oral etoposide therapy (VP 16–213). Twelve patients had metastatic GTD. Fifty-nine patients achieved biochemical remission. One patient had marked nausea and vomiting and the therapy was switched to a methotrexate/folinic acid regimen. Three patients developed relapse of GTD, giving a relapse rate of 5.1%. Etoposide is an active drug against choriocarcinoma. Its use should not be restricted to drug-resistant GTD. Cancer 58:14–17, 1986.This publication has 5 references indexed in Scilit:
- Methotrexate with citrovorum factor rescue in gestational trophoblastic diseaseAmerican Journal of Obstetrics and Gynecology, 1985
- Use of oral VP16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic diseaseAmerican Journal of Obstetrics and Gynecology, 1984
- CHEMOTHERAPY WITH THE MODIFIED BAGSHAWE PROTOCOL FOR POOR PROGNOSIS METASTATIC TROPHOBLASTIC DISEASE1982
- Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinomaPublished by Elsevier ,1980
- THE PATHOLOGY OF CHORIOCARCINOMAAnnals of the New York Academy of Sciences, 1971